Compare POR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POR | RYTM |
|---|---|---|
| Founded | 1889 | 2008 |
| Country | United States | United States |
| Employees | 2915 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.8B |
| IPO Year | 1994 | 2017 |
| Metric | POR | RYTM |
|---|---|---|
| Price | $50.62 | $88.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $48.55 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.2M | 475.3K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $3,576,000,000.00 | N/A |
| Revenue This Year | $6.94 | $55.34 |
| Revenue Next Year | $5.83 | $86.06 |
| P/E Ratio | $133.47 | ★ N/A |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $39.55 | $60.71 |
| 52 Week High | $54.62 | $122.20 |
| Indicator | POR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 50.75 |
| Support Level | $50.29 | $82.43 |
| Resistance Level | $51.43 | $92.51 |
| Average True Range (ATR) | 1.02 | 3.73 |
| MACD | 0.18 | -0.10 |
| Stochastic Oscillator | 69.81 | 51.93 |
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.